Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CD69 | Q07108 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10627261 | 0.87 | ALDH1A1 (0.30) | — | |
| SCHEMBL9004174 | 0.82 | ELANE (0.36) | ELANECD69 | |
| SCHEMBL29385796 | 0.82 | ELANE (0.31) | ELANECD69 | |
| SCHEMBL9416882 | 0.82 | ELANE (0.31) | ELANECD69 | |
| SCHEMBL5051101 | 0.80 | ELANE (0.35) | ELANECD69 | |
| SCHEMBL8636490 | 0.80 | CYP1A2 (0.33) | ELANECD69CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL10583884 | 0.79 | ELANE (0.34) | ELANECD69 | |
| SCHEMBL29509823 | 0.79 | USP2 (0.33) | — | |
| SCHEMBL1619437 | 0.78 | KMT2A (0.33) | — | |
| SCHEMBL6048235 | 0.77 | ELANE (0.35) | ELANECD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1437356-B1 | Copper complexes and the use thereof | LANXESS DEUTSCHLAND GMBH (DE) | 2006-03-29 | — | — | EP | claimed |
| US-20040198997-A1 | Copper complexes and their use | LANXESS DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | claimed |
| EP-1437356-A1 | Copper complexes and the use thereof | Bayer Chemicals AG (DE) | 2004-07-14 | — | — | EP | claimed |
| US-7179946-B2 | Copper complexes and their use | LANXESS DEUTSCHLAND GMBH (DE) | 2007-02-20 | — | — | US | disclosed |
| EP-1437356-B1 | Copper complexes and the use thereof | LANXESS DEUTSCHLAND GMBH (DE) | 2006-03-29 | — | — | EP | disclosed |
| US-6946577-B2 | Process for the production of aminodiphenylamines | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-20 | — | — | US | disclosed |
| US-20040198997-A1 | Copper complexes and their use | LANXESS DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20040143139-A1 | Process for the production of aminodiphenylamines | LANXESS DEUTSCHLAND GMBH (DE) | 2004-07-22 | — | — | US | disclosed |
| EP-1437340-A1 | Process for the preparation of aminodiphenylamines | Bayer Aktiengesellschaft (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-1437356-A1 | Copper complexes and the use thereof | Bayer Chemicals AG (DE) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143139-A1 | Process for the production of aminodiphenylamines | NUDT1, ITPA, NAAA | ELANE 2545/4885CD69 2779/4885CYP1A2 300/4885 |
| US-20040198997-A1 | Copper complexes and their use | SOD1, SOD3, ITPA | ELANE 1007/4885CD69 4787/4885CYP1A2 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.